Smoking in patients receiving psychotropic medications - A pharmacokinetic perspective

被引:149
作者
Desai, HD
Seabolt, J
Jann, MW [1 ]
机构
[1] Mercer Univ, So Sch Pharm, Dept Pharm Practice & Pharmaceut Sci, Atlanta, GA 30341 USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
关键词
D O I
10.2165/00023210-200115060-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine. The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking. Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared with nonsmokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties. Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.
引用
收藏
页码:469 / 494
页数:26
相关论文
共 95 条
[1]  
Aitchison Katherine J., 2000, Drug Metabolism and Drug Interactions, V16, P15
[2]  
Amchin J, 1999, J CLIN PHARMACOL, V39, P252
[3]   Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors [J].
Balant-Gorgia, AE ;
Gex-Fabry, M ;
Genet, C ;
Balant, LP .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :105-115
[4]   A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene:: association with tardive dyskinesia in schizophrenia [J].
Basile, VS ;
Özdemir, V ;
Masellis, M ;
Walker, ML ;
Heltzer, HY ;
Lieberman, JA ;
Potkin, SG ;
Alva, G ;
Kalow, W ;
Macciardi, FM ;
Kennedy, JL .
MOLECULAR PSYCHIATRY, 2000, 5 (04) :410-417
[5]   ABSENCE OF EFFECT OF CIGARETTE-SMOKING ON SERUM CONCENTRATIONS OF SOME ANTICONVULSANTS IN EPILEPTIC PATIENTS [J].
BENETELLO, P ;
FURLANUT, M ;
PASQUI, L ;
CARMILLO, L ;
PERLOTTO, N ;
TESTA, G .
CLINICAL PHARMACOKINETICS, 1987, 12 (04) :302-304
[6]   NICOTINE AND COTININE ELIMINATION PHARMACOKINETICS IN SMOKERS AND NONSMOKERS [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (03) :316-323
[7]   SMOKING AND TARDIVE-DYSKINESIA [J].
BINDER, RL ;
KAZAMATSURI, H ;
NISHIMURA, T ;
MCNIEL, DE .
BIOLOGICAL PSYCHIATRY, 1987, 22 (10) :1280-1282
[8]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[9]   CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [J].
Carrillo, JA ;
Benitez, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (06) :605-608
[10]  
CHAN L, 1999, PHARMACOTHERAPY SELF, P85